Rate My Professor Jim Poli

James E. Polli, PhD, is Professor of Pharmaceutical Sciences and Ralph F. Shangraw/Noxell Endowed Chair in Industrial Pharmacy and Pharmaceutics in the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, University of Maryland, Baltimore. He earned a PhD in Pharmaceutics from the University of Michigan and a BS in Pharmacy from Philadelphia College of Pharmacy and Science. Polli holds leadership positions as Co-Director of the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), an FDA-funded collaboration, and Co-Director of the Center for Research on Complex Generics (CRCG). He directs the online MS in Regulatory Science program, has advised 25 PhD graduates, served as Editor of Pharmaceutical Research for 12 years, and is a Fellow of the American Association of Pharmaceutical Scientists (AAPS). Recognized as an MPower Professor, his career contributions span education, research leadership, and editorial roles in pharmaceutics.

Polli's research centers on oral drug absorption, maximizing oral bioavailability via formulation and chemical strategies, and establishing public quality standards for oral dosage forms. Notable publications include "Efficiency of single pharmaceutical surfactants to mimic intestinal biorelevant media solubilization and dissolution of etravirine: Comparison of intrinsic and film dissolution models" (Oktay and Polli, 2024, European Journal of Pharmaceutical Sciences), "Differential effects of metformin-mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial" (Metry et al., 2022, Clinical and Translational Science), "Dissolution-hollow fiber membrane (D-HFM) system to anticipate biopharmaceutics risk of tablets and capsules" (Adhikari et al., 2023, Journal of Pharmaceutical Sciences), "In Vitro Studies Are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-release Solid Oral Dosage Forms" (Polli, 2008, AAPS Journal), "Generic lamotrigine versus brand-name LAMICTAL bioequivalence in epilepsy patients: a field test of the FDA bioequivalence standard" (Ting et al., 2015, Epilepsia), and "Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities" (Polli and Ginski, 1998, Pharmaceutical Research). His impact is evidenced by major honors: 2024 American Association of Colleges of Pharmacy Volwiler Research Achievement Award, 2022 AAPS Global Leadership Award, 2021 TOPRA Education Award, American Pharmacists Association Takeru Higuchi Research Prize, 1998 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technology, and 2008 AAPS Fellow.